Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
72 hedge funds and large institutions have $195M invested in Jounce Therapeutics, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 27 increasing their positions, 16 reducing their positions, and 9 closing their positions.
156% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 9
69% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 16
24% more funds holding
Funds holding: 58 → 72 (+14)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
28% less capital invested
Capital invested by funds: $270M → $195M (-$75.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$18.4M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$4.27M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.02M |
| 5 |
BlackRock
New York
|
+$2.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.68M |
| 2 |
DM
Deerfield Management
New York
|
-$4.73M |
| 3 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$2.2M |
| 4 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$2.01M |
| 5 |
Millennium Management
New York
|
-$1.91M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCM
76
Laurion Capital Management
New York
| – | -$880K | -40,000 | Closed |
|
77
HSBC Holdings
London,
United Kingdom
| – | -$256K | -11,620 | Closed |
|
|
PP
78
Paloma Partners
Greenwich,
Connecticut
| – | -$212K | -9,612 | Closed |
|
|
TRCT
79
Tower Research Capital (TRC)
New York
| – | -$74K | -3,357 | Closed |
|
80
UBS Group
Zurich,
Switzerland
| – | -$24K | -1,110 | Closed |
|
|
FMA
81
FNY Managed Accounts
New York
| – | -$9K | -440 | Closed |
|
JNCE Hedge Fund Activity: Q2 2017 in Review
72 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q2 2017, worth a combined $195M — down 28% from $270M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new JNCE positions and 9 closed out — a net gain of 14 holders — while 27 added to existing stakes and 16 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $18.4M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $5.68M sold.
- 72 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q2 2017, up from 58 in Q1 2017.
- Funds reported $195M of Jounce Therapeutics, Inc. Common Stock stock for Q2 2017, down 28% quarter-over-quarter.
- 23 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q2 2017 and 9 closed out, a net change of +14 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q2 2017 was Wellington Management Group, an estimated $18.4M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q2 2017 was EcoR1 Capital, an estimated $5.68M sold.
Based on aggregated 13F filings for Q2 2017.